Day: April 10, 2023

WASHINGTON, April 10, 2023 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that its Board of Directors (the “Board”) elected Elsy Boglioli as a director of the Company effective on April 7, 2023. Ms. Boglioli joins the Board as an independent director, following the action of the Board on April 6, 2023 to increase its overall size to ten directors from nine directors effective April 7, 2023. Ms. Boglioli, age 41, founded and has been the Chief Executive Officer of Bio-Up, a consulting firm providing advisory services to companies in the healthcare technology field, since September 2019. From December 2017 to August 2019, Ms. Boglioli served as Executive Vice President and Chief Operating Officer of Cellectis, a clinical-stage biopharmaceutical company focusing on cell therapies. From January 2006 to November...

CANTON, Mass., April 10, 2023 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that first quarter of fiscal year 2023 financial results will be reported after the market closes on Wednesday, May 10th. Management will host a conference call at 5:00 p.m. Eastern Time on May 10th to discuss the results of the quarter and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on...

BOSTON, April 10, 2023 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that new data from studies with NUZYRA® (omadacycline) will be presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). The hybrid conference will be held April 15-18 at the Bella Center Copenhagen in Copenhagen, Denmark. View ECCMID scientific program here. “We continue to generate new data to enhance understanding of NUZYRA’s utility, both to enhance clinicians’ confidence in prescribing it for patients with life-threatening, community-acquired infections as...

CLEVELAND, April 10, 2023 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the acceptance of three abstracts at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place from May 16-20, 2023 in Los Angeles, CA. Accepted abstracts include new data on three internally developed investigational preclinical gene therapy product candidates from its adeno-associated virus (AAV) ophthalmology program, including ABO-504 for Stargardt disease, ABO-503 for X-linked retinoschisis (XLRS) and ABO-505 for autosomal dominant optic atrophy (ADOA). “At ASGCT, the data we present will highlight the potential of our proprietary AAV capsids and gene constructs to express recombinant protein in target eye tissues and rescue mutant phenotypes,” said Brian Kevany, Ph.D., Chief Technical...

Line Designed to Increase Speed of Custom-Sized Cell Development and Customer Qualification FREMONT, Calif., April 10, 2023 (GLOBE NEWSWIRE) — Enovix Corporation (“Enovix”) (Nasdaq: ENVX), an advanced silicon battery company, today announced that it has issued purchase orders for its Agility Line, the company’s advanced, high-speed R&D line, which is designed to increase the speed of its battery customization and customer qualification processes. Enovix also announced it completed its Gen2 Autoline equipment orders. “Our team continues to deliver on the commitments we laid out when we announced our journey to scale,” said Dr. Raj Talluri, President and CEO of Enovix. “Our Agility Line is designed to increase the speed of our customer qualification process and accelerate time-to-market for new, custom cells. This line is an...

Figure 1 Bomboré Plan Map OverviewVANCOUVER, British Columbia, April 10, 2023 (GLOBE NEWSWIRE) — Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (the “Company” or “Orezone”) is pleased to provide drill results from its ongoing oxide drill program at its Bomboré Gold Mine. The release includes results from the Phase III resource definition program and drilling of exploration targets outside of the current resources along known mineralized trends. These results successfully:Confirmed the continuity of near-surface oxide mineralization within established resource areas. Demonstrated the potential to further expand the oxide resource along strike. Highlighted the potential to delineate additional oxide resources, supporting the Company’s goal of offsetting mine depletion. Ongoing drilling throughout 2023 will further test and...

SAFETY HARBOR, Florida, April 10, 2023 (GLOBE NEWSWIRE) — Eightco Holdings Inc. (NASDAQ: OCTO) has announced that it will be participating in a Non-Deal Roadshow (NDRs) commencing on May 2, 2023, following its 2022 annual results on April 17, 2023, and will be hosted by a leading full-service investment bank that provides a range of services to its clients, including corporate finance, equity research, sales and trading and investment banking. The investment firm focuses on small to mid-cap companies in various sectors, including healthcare, technology, energy, and mining. This decision was made after Eightco Holdings received unsolicited proposals to conduct strategic NDRs. NDRs offer investors a comprehensive look at a company’s business model that press releases, presentations and other public documents cannot. NDRs are a common...

TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 10, 2023 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for PMN310 for the treatment of AD. “This submission is an important milestone for the ProMIS team as we advance our lead compound, PMN310, toward the clinic. We are excited to continue the development of PMN310 to potentially provide a new treatment option with a differentiated profile for patients with Alzheimer’s...

Revenues for First Quarter of 2023 Estimated to Reach $5.5 Million, a 9th Consecutive Record-Breaking Quarter; Quarterly Operative Cash Burn Rate Significantly Reduced to Approximately $0.3 million, Reflecting the Company’s Continuous Efficiency Measures Tel Aviv, Israel, April 10, 2023 (GLOBE NEWSWIRE) —  Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) (“Alarum” or the “Company”), a global provider of enterprise and consumers internet access solutions, today provided key financial metrics guidance for the first quarter of 2023. Based upon a preliminary, unaudited review, Alarum expects to report revenues of approximately $5.5 million for the first quarter of 2023, compared to revenues of $3.7 million reported in the first quarter of 2022, representing approximately 50% growth. Revenue growth continues to be driven by the Company’s...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO, April 10, 2023 (GLOBE NEWSWIRE) — Angus Gold Inc. (TSX-V: GUS) (“Angus” or the “Company”) is pleased to announce a non-brokered private placement consisting of up to 4,000,000 flow-through shares of the Company (“FT Shares”) at a price of C$1.00 per FT Share and up to 1,500,000 hard dollar shares of the Company (“Hard Shares”) at a price of C$0.72 per Hard Share for aggregate gross proceeds of up to C$5,080,000 (the “Offering”). The net proceeds from the Offering are expected to be used to fund exploration on the Company’s projects in Ontario and for working capital purposes. The Company has agreed to incur and renounce “Canadian exploration...